Skip to main content
Canna~Fangled Abstracts

A Guide to Targeting the Endocannabinoid System in Drug Design.

By April 16, 2020April 23rd, 2020No Comments
2020 Apr 16;21(8). pii: E2778. doi: 10.3390/ijms21082778.

Abstract

The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metabolism, as well as cell growth and proliferation. Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands’ synthesizing and degrading enzymes, are promising therapeutic targets. Their modulation has been employed in or extensively studied as a treatment of multiple diseases. However, due to a complex nature of ECS and its crosstalk with other biological systems, the development of novel drugs turned out to be a challenging task. In this review, we summarize potential therapeutic applications for ECS-targeting drugs, especially focusing on promising synthetic compounds and preclinical studies. We put emphasis on modulation of specific proteins of ECS in different pathophysiological areas. In addition, we stress possible difficulties and risks and highlight proposed solutions. By presenting this review, we point out information pivotal in the spotlight of ECS-targeting drug design, as well as provide an overview of the current state of knowledge on ECS-related pharmacodynamics and show possible directions for needed research.

KEYWORDS: CB1, CB2, ECS, FAAH, MAGL, endocannabinoid system, molecular target

PMID: 32316328
DOI: 10.3390/ijms21082778

Leave a Reply